title: Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study.
abstract: The malignant biological behavior of breast cancer remains obscure on diagnostic images, although understanding the grade of such malignancy is important for selecting appropriate treatment. Therefore, malignancy grades in operable breast cancer were evaluated using positron emission tomography/computed tomography (PET/CT) in a multicenter setting. We prospectively examined the features and prognosis of 344 patients (mean age ± SD: 58.0 ± 12.5 years) with clinical stages I-III breast cancer, who underwent surgical intervention without induction therapy between January 2006 and December 2011. Maximum standardized uptake values (maxSUV) obtained from whole-body fluorodeoxyglucose-PET/CT immediately before surgery were assessed to predict the malignant aggressiveness of tumors including the recurrence-free survival of the patients. Variations in maxSUV among institutions, which are limitations of PET assessments in multicenter studies, were adjusted using a phantom study. The median follow up period was 52 months. The patients were divided into groups according to cut-off maxSUV (≤3.0 vs. >3.0) values established from receiver operating characteristic analysis of recurrence (area under the curve = 0.713). A higher maxSUV was significantly associated with a higher T-factor (p < 0.0001), N-factor (p = 0.0049), nuclear grade (p < 0.0001), negative for estrogen (p = 0.0309), and progesterone receptors (p = 0.0063), positive for human epidermal growth factor receptor 2 (p = 0.0012), lymph node metastasis (p = 0.0128), and vascular invasion (p = 0.0110). Multivariate analysis using Cox proportional hazard regression model revealed high maxSUV and negative estrogen receptor status as significantly prognostic factors (p = 0.033 and p = 0.004, respectively). This study demonstrated that maxSUV on PET/CT as well as estrogen receptor status is useful to predict malignancy grades and the prognosis of patients with breast cancer.
authors.affiliation: Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima, Hiroshima, 734-0037, Japan, takayukikadoya@gmail.com.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Kadoya
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Aogi
authors.forename: Sachiko
authors.initials: S
authors.lastname: Kiyoto
authors.forename: Norio
authors.initials: N
authors.lastname: Masumoto
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Sugawara
authors.forename: Morihito
authors.initials: M
authors.lastname: Okada
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000601:surgery; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism*; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011379:Prognosis; D011446:Prospective Studies; D012372:ROC Curve; D012307:Risk Factors; D014057:Tomography, X-Ray Computed
chemical_list: D014408:Biomarkers, Tumor; D019788:Fluorodeoxyglucose F18
references.citation: J Nucl Med. 2004 Sep;45(9):1480-7
references.pmid: 15347714
references.citation: Breast. 2013 Oct;22(5):958-63
references.pmid: 23756383
references.citation: Breast Cancer Res Treat. 2011 Nov;130(2):489-98
references.pmid: 21837481
references.citation: Ann Oncol. 2006 Dec;17(12):1772-6
references.pmid: 17071934
references.citation: Ann Oncol. 2011 Aug;22(8):1736-47
references.pmid: 21709140
references.citation: Clin Breast Cancer. 2012 Oct;12(5):340-6
references.pmid: 23040002
references.citation: Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1069-76
references.pmid: 20130860
references.citation: Acta Radiol. 2009 Nov;50(9):979-83
references.pmid: 19863406
references.citation: Eur J Nucl Med Mol Imaging. 2007 Mar;34(3):392-404
references.pmid: 17033848
references.citation: Ann Oncol. 2009 Aug;20(8):1319-29
references.pmid: 19535820
references.citation: Jpn J Clin Oncol. 2011 Jul;41(7):890-6
references.pmid: 21613306
references.citation: Breast Cancer Res Treat. 2011 Nov;130(1):267-72
references.pmid: 21590272
references.citation: Breast Cancer Res Treat. 2012 Jan;131(1):117-26
references.pmid: 21935602
references.citation: Breast Cancer Res Treat. 2012 Jan;131(2):357-69
references.pmid: 21960111
references.citation: Eur J Nucl Med Mol Imaging. 2012 May;39(5):852-63
references.pmid: 22392069
references.citation: Ann Oncol. 2013 Apr;24(4):1005-10
references.pmid: 23136224
references.citation: Cancer. 2012 Nov 15;118(22):5454-62
references.pmid: 22517371
references.citation: J Clin Oncol. 2012 Jan 10;30(2):184-90
references.pmid: 22162590